Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term imatinib mesylate. Found 12 abstracts

Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Annals of Oncology. 2012 May;23(5):1335-40.   PMCID: PMC3493136 [Available on 2013/5/1]
Miller SJ, Alam M, Andersen JS, Berg D, Bichakjian CK, Bowen GM, Cheney RT, Glass LF, Grekin RC, Ho AL, Kessinger A, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Perlis CS, Shaha AR, Tuli M, Urist MM, Wang LC, Zic JA. Dermatofibrosarcoma Protuberans. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):312-8.   PMCID: not NIH funded
von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Aug;10(8):951-60.   PMCID: not NIH funded
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Annals of Oncology. 2011 Nov;22(11):2523-9.   PMCID: not NIH funded
Blay JY, von Mehren M, Blackstein ME. Perspective on Updated Treatment Guidelines for Patients With Gastrointestinal Stromal Tumors. Cancer. 2010 Nov;116(22):5126-37.   PMCID: NIH funded
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Belinsky MG, Skorobogatko YV, Rink L, Pei JM, Cai KQ, Vanderveer LA, Riddell D, Merkel E, Tarn C, Eisenberg BL, von Mehren M, Testa JR, Godwin AK. High Density DNA Array Analysis Reveals Distinct Genomic Profiles in a Subset of Gastrointestinal Stromal Tumors. Genes Chromosomes & Cancer. 2009 Oct;48(10):886-96.   PMCID: PMC2830286
O'Brien S, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Radich JP, Shah NP, Smith BD, Snyder DS, Talpaz M, Wetzler M. Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 2009 Oct;7(9):984-1023.   PMCID: not NIH funded
Ochs MF, Rink L, Tarn C, Mburu S, Taguchi T, Eisenberg B, Godwin AK. Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data. Cancer Research. 2009 Dec;69(23):9125-32.   PMCID: PMC2789202
von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematology-Oncology Clinics of North America. 2005 Jun;19(3):547-+.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term imatinib mesylate

imatinib mesylate imatinib phase-ii trial gist c-kit prognostic-factors sarcoma therapy phase-ii tyrosine kinase inhibitor gastrointestinal stromal tumors dose imatinib interstitial-cells inhibitor radiation therapy NCCN Clinical Practice Guidelines chronic myeloid-leukemia adjuvant term-follow-up kit mutations tyrosine kinase mutations 1989 sner mc-archives of surgery-v124-p191 of-function mutations NCCN Guidelines kit surgical-management desmoid tumor nilotinib differential-diagnosis sunitinib non-melanoma Mohs surgery component analysis dose complete cytogenetic soft-tissue sarcomas soft tissue growth-factor chemotherapy microarray data 2008 matteo d-p am soc clin oncol-v26 Anti-angiogenic therapy mohs micrographic surgery donor lymphocyte infusions guidelines 2007 arthur ga-j natl compr canc ne-v5-p557 2008 orge s-j clin oncol-v26 excision synchronous occurrence registry residual disease prognostic implications phase-iii of-function matrix factorization platinum-resistant network triple angiokinase inhibitor survival gastrointestinal Bevacizumab breast-cancer Network soft tissue extremity sarcoma recurrence potential therapeutic target laparoscopic wedge resection epithelial ovarian karyotyping young-adults familial adenomatous polyposis stem-cell transplantation randomized-trial neoadjuvant chemotherapy of-the-literature cancer retroperitoneal sarcomas gynecologic-oncology-group leukemia dermatofibrosarcoma protuberans follow-up tyrosine-kinase inhibitor lung-cancer European Society of Medical Oncology hematologic response diagnosis PDGFR-alpha adjuvant imatinib patients receiving imatinib KIT cytogenetic 2003 silva cm-pathol oncol res-v9-p13 long-term outcomes inhibitors stromal gastrointestinal-tumors-imatinib-practice guideline-protein tyrosine-kinases-sunitinib beta-catenin gene skin fibroblast-growth-factor Ovarian cancer allogenic HSCT surgery factor xiiia 2007 orge s-j clin oncol-v25 tyrosine-kinase polymerase-chain-reaction stromelysin-3 expression targeted therapy primary extremity sarcoma deep fibromatosis beta-catenin-desmoid tumor-GIST-imatinib-KIT management endothelial-cells response radiation-therapy Tyrosine kinase National Comprehensive Cancer bone-marrow-transplantation in-situ hybridization identification dasatinib positron-emission-tomography chronic myelogenous trial neoplasms transplantation wide fibromatosis cell european-organization kit activation stromal tumor
Last updated on Friday, January 03, 2020